Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma

Bookmark
Investigational drug late phase More information Active drug More information Moderate burden on patient More information

Trial Details

Sponsor: M.D. Anderson Cancer Center (other)

Phase: 2

Start date: July 2, 2025

Planned enrollment: 40

Trial ID: NCT06940518
Copy trial ID
More trial details at ClinicalTrials.gov More info

chevron Show Summary from Sponsor

Investigational Drug AI Analysis

chevron Show for: Ivonescimab (AK112/SMT112)

HealthScout AI Analysis

Goal: Assess whether ivonescimab monotherapy provides clinically meaningful antitumor activity in previously treated, locally advanced or metastatic clear cell renal cell carcinoma, focusing on objective response rate and 24-week disease control by RECIST 1.1, and to characterize safety.

Patients: Adults with histologically or cytologically confirmed metastatic/advanced RCC with a clear cell component, ECOG 0–2, at least one measurable lesion, and progression after at least one prior systemic line that included a PD-1/PD-L1 inhibitor in the advanced/metastatic setting. Two cohorts: cohort 1 excludes prior VEGF/HIF-2α agents; cohort 2 requires prior VEGF-directed therapy and may include prior HIF-2α inhibitors. Key exclusions include uncontrolled hypertension, recent major surgery or significant bleeding/thromboembolic events, active significant autoimmune disease requiring systemic therapy, symptomatic or unstable CNS metastases, significant GI perforation/fistula history, and unresolved grade ≥2 toxicities from prior therapy.

Design: Phase 2, single-arm, non-randomized, open-label study with two parallel cohorts based on prior VEGF/HIF-2α exposure; planned enrollment of 40 participants.

Treatments: Ivonescimab administered intravenously every 3 weeks as monotherapy. Ivonescimab is a first-in-class bispecific antibody targeting PD-1 and VEGF with a tetravalent design enabling cooperative binding; VEGF presence increases PD-1 affinity and vice versa, aiming to simultaneously relieve tumor-induced immunosuppression and inhibit angiogenesis. Early-phase data across solid tumors showed manageable safety and antitumor activity with an approximate 25% objective response rate; in PD-L1–positive NSCLC, a phase 3 study reported improved progression-free survival versus pembrolizumab. The agent has a 6–7 day half-life and uses Fc-silencing mutations to reduce unwanted immune effector functions.

Outcomes: Primary endpoints include objective response rate and 24-week disease control rate per RECIST 1.1, and incidence of adverse events graded by NCI CTCAE. Secondary endpoints include overall survival, progression-free survival, duration of response, and further safety characterization.

Burden on patient: Moderate. Participation requires regular IV infusions every 3 weeks, serial safety labs, and imaging for RECIST assessments, which are typical for phase 2 immunotherapy studies. No intensive pharmacokinetic sampling or mandatory biopsies are specified, reducing procedural burden; however, eligibility and on-study monitoring for cardiovascular, hepatic, and coagulation parameters, as well as management of potential immune-related and VEGF-related toxicities, may necessitate additional clinic visits and evaluations compared with standard follow-up.

Eligibility More information

chevron Show Criteria

Sites (1)

Sort by distance to:
Clear

MD Anderson Cancer Center

Houston, Texas, 77030, United States

[email protected] / 713-563-4585

Status: Recruiting

Back to trials list